|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.
|
19287382 |
2009 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
CTD_human |
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
|
19287384 |
2009 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
The identification of somatic calreticulin (CALR) mutations can be used to confirm the diagnosis of a myeloproliferative disorder in Philadelphia chromosome-negative, JAK2 and MPL wild type patients with thrombocytosis.
|
27114372 |
2016 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
KANK1-PDGFRB is a unique example of a thrombocythemia-associated oncogene that does not signal via JAK2.
|
21685469 |
2011 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
More studies are needed to prove the role of JAK2 in ineffective erythropoiesis, iron metabolism and thrombocytosis and to determine if using JAK2 inhibitors in thalassemic patients can be a potential therapeutic option.
|
22203487 |
2012 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
JAK2 617 HP is an adequate test in differential diagnosis for both erythrocytosis and thrombocytosis.
|
18575865 |
2008 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We propose that JAK2 and MPL expression levels regulate megakaryocytic proliferation vs differentiation in both normal and pathological conditions, and that JAK2 chemical inhibitors could promote a paradoxical thrombocytosis when used at suboptimal doses.
|
25143485 |
2014 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
|
20154217 |
2010 |
|
Thrombocytosis
|
0.500 |
Biomarker
|
disease |
LHGDN |
JAK2 617 HP is an adequate test in differential diagnosis for both erythrocytosis and thrombocytosis.
|
18575865 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis.
|
18160670 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, when a patient presents with isolated thrombocytosis and a positive JAK2 V617F assay, particularly a young woman, the possibility of PV must always be considered because of plasma volume expansion.
|
29516275 |
2018 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated the JAK2 V617F, CALR and STAT5 activation status in patients with CML and thrombocytosis (CML-T) that mimicked ET, trying to identify a common mechanism for thrombocytosis in MPN.
|
26754830 |
2016 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Investigation for polycythaemia and thrombocytosis showed JAK2 positive myeloproliferative neoplasm.A diagnosis of AOP infarction is often missed or delayed because it is rare and presents with variable neurological symptoms.
|
29592977 |
2018 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In the case of a patient with erythrocytosis and other signs of myeloproliferation, such as leukocytosis, thrombocytosis or splenomegaly, the diagnosis of polycythemia vera (PV) is likely, and I test serum erythropoietin and JAK2 mutations first.
|
22157736 |
2012 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To our knowledge, this is the first case of ET caused by JAK2-T875N mutation with a family history of thrombocytosis and cerebral infarction.
|
31428969 |
2019 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Refractory anemia with ring sideroblasts (RARS-T) associated with marked thrombocytosis is a myelodysplastic/myeloproliferative neoplasm associated with both SF3B1 and JAK2 or MPL mutations.
|
24507814 |
2013 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
His postoperative management included the examination of his peripheral blood as well as bone marrow, which confirmed that the cause of his elevated platelet count was due to JAK2 V617F mutation that is treated by hydroxyurea and aspirin after being discharged from the hospital.
|
18534315 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have identified 2 families with hereditary thrombocytosis presenting novel heterozygous germ-line mutations of JAK2.
|
24398328 |
2014 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
|
23594705 |
2013 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Further investigations for intracoronary thrombus with no underlying atherosclerotic disease revealed positive Janus kinase 2 (JAK2) V617F gene mutation, and this was consistent with a diagnosis of ET with elevated platelet count.
|
22686448 |
2012 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis.
|
18059483 |
2008 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recently, germline mutations in Janus kinase 2 (JAK2) and MPL, two genes frequently mutated in sporadic MPD, have been shown to cause inherited thrombocytosis.
|
25195195 |
2014 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph(+) CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.
|
23613267 |
2013 |
|
Thrombocytosis
|
0.500 |
GeneticVariation
|
disease |
LHGDN |
The quantitative JAK2 V617F neutrophil allele burden does not correlate with thrombotic risk in essential thrombocytosis.
|
17507997 |
2007 |